Chemotherapy with or without vaccine for HPV-related throat cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial compares standard chemotherapy alone versus chemotherapy combined with an investigational vaccine (PRGN-2009) before surgery for newly diagnosed HPV-positive oropharyngeal (throat) cancer. The goal is to see if adding the vaccine improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have newly diagnosed, surgically removable HPV-positive throat cancer that has not spread to distant organs.
- You must be 18 years or older.
- You must be in generally good health (able to care for yourself, up and about).
- If you smoke, you must have less than 10 pack-years total (for example, 1 pack a day for 10 years) or quit more than 10 years ago.
- You must be willing to have a biopsy and imaging (PET/CT) before starting treatment.
- You must agree to use effective birth control during and after treatment, if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if monitoring cancer DNA left in your blood after surgery can help decide if you need additional treatment. It is for people with HPV-positive oropharynx (throat) cancer who have a certain amount of cancer DNA detected before surgery.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This trial tests whether using a lower intensity (reduced) chemo-radiation plan can work for some people with HPV-related oropharyngeal (throat) cancer without losing effectiveness. It may help reduce side effects while still controlling the cancer.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
This trial is testing a surgical approach for people with HPV-related oropharyngeal cancer that is stage I or II (but not the very smallest). The goal is to see if removing the tumor through the mouth and taking out neck lymph nodes is effective and safe. It may be an option if you are healthy enough for surgery.
Hear when a new Drug Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.